pulmonary fibrosis
pulmonary fibrosis
Explore linked clinical trials. Standard reference: MONDO:0002771203 results · Page 1 of 9
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ORJ-001 for the Treatment of IPF | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07869147 | |
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07868419 | |
| Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Not applicable | 2026-10-09 | NCT07673237 | |
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07284459 | |
| Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD | Cough, Fibrosis, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Hypersensitivity, Signs and Symptoms, Signs and Symptoms, Respiratory, hypersensitivity pneumonitis, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, pulmonary fibrosis, respiratory system disorder, sarcoidosis | Not yet recruiting | Phase 4 | 2026-10-08 | NCT07859839 | |
| Analysis of Specimens From Individuals With Pulmonary Fibrosis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Fibrosis, Hemic and Lymphatic Diseases, Hermansky-Pudlak syndrome, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, albinism, blood coagulation disease, blood platelet disease, eye disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary skin disorder, hypopigmentation of the skin, inborn disorder of amino acid metabolism, inborn errors of metabolism, inherited blood coagulation disorder, interstitial lung disease, lung disorder, metabolic disease, oculocutaneous albinism, platelet storage pool deficiency, pulmonary fibrosis, respiratory system disorder, skin disorder, skin pigmentation disorder | Active, not recruiting | Not stated | 2026-10-08 | NCT00084305 | |
| Role of Genetic Factors in the Development of Lung Disease | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Fibrosis, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Hypersensitivity, Immediate, Infant, Newborn, Diseases, Malformations of Cortical Development, Group I, Neoplasms, Multiple Primary, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, asthma, bronchial disorder, central nervous system malformation, cerebral cortical dysplasia, cystic fibrosis, hamartoma, hereditary disease, hereditary neoplastic syndrome, immune system disorder, inherited neurodegenerative disorder, interstitial lung disease, liver disorder, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, obstructive lung disease, pancreas disorder, pulmonary emphysema, pulmonary fibrosis, pulmonary sarcoidosis, respiratory system disorder, sarcoidosis, tuberous sclerosis | Recruiting | Not stated | 2026-10-08 | NCT00001532 | |
| Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Eye Diseases, Hereditary, Fibrosis, Hemic and Lymphatic Diseases, Hermansky-Pudlak syndrome, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, albinism, blood coagulation disease, blood platelet disease, digestive system disorder, eye disorder, gastroenteritis, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary skin disorder, hypopigmentation of the skin, inborn disorder of amino acid metabolism, inborn errors of metabolism, inflammatory bowel disease, inherited blood coagulation disorder, interstitial lung disease, intestinal disorder, lung disorder, metabolic disease, oculocutaneous albinism, platelet storage pool deficiency, pulmonary fibrosis, respiratory system disorder, skin disorder, skin pigmentation disorder | Recruiting | Not stated | 2026-10-08 | NCT00001456 | |
| A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Not yet recruiting | Phase 2 | 2026-10-07 | NCT07862634 | |
| Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Enrolling by invitation | Phase 3 | 2026-10-06 | NCT04905693 | |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Fibrosis, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, hypersensitivity pneumonitis, immune system disorder, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-10-05 | NCT06329401 | |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-02 | NCT06951217 | |
| Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06940427 | |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-09-30 | NCT06238622 | |
| Daoyin Technique for Improving Exercise Endurance in IPF | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Not applicable | 2026-09-29 | NCT07019714 | |
| Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, interstitial lung disease, lung disorder, musculoskeletal system disorder, pulmonary fibrosis, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, skin disorder, systemic sclerosis | Not yet recruiting | Not stated | 2026-09-25 | NCT07839221 | |
| A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT07036523 | |
| IPF Longitudinal Natural History Study | Disease Attributes, Disease Progression, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Not stated | 2026-09-22 | NCT07560189 | |
| A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-09-21 | NCT07652658 | |
| Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs | Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Disease Attributes, Fibrosis, Infant, Newborn, Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, cystic fibrosis, hereditary disease, interstitial lung disease, lung disorder, obstructive lung disease, pancreas disorder, pulmonary arterial hypertension, pulmonary emphysema, pulmonary fibrosis, pulmonary hypertension, respiratory system disorder | Enrolling by invitation | Not stated | 2026-09-18 | NCT04930289 | |
| Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07687459 | |
| A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-09-17 | NCT07516951 | |
| Pulmonary Fibrosis Foundation Community Registry | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Not stated | 2026-09-17 | NCT05382572 | |
| Post Acute Sequelae of COVID-19 | COVID-19, Coronaviridae Infections, Fibrosis, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, interstitial lung disease, lung disorder, pneumonia, pulmonary fibrosis, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-09-17 | NCT04964115 | |
| Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Not stated | 2026-09-15 | NCT07820254 |